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IMPORTANCE Few cardiovascular outcomes trials have been conducted for obesity
treatments. Withdrawal of 2 marketed drugs has resulted in controversy about the
cardiovascular safety of obesity agents.
OBJECTIVE To determine whether the combination of naltrexone and bupropion increases
major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke,
or nonfatal myocardial infarction) compared with placebo in overweight and obese patients.
DESIGN, SETTING, AND PARTICIPANTS Randomized,multicenter, placebo-controlled,
double-blind noninferiority trial enrolling 8910 overweight or obese patients at increased
cardiovascular risk from June 13, 2012, to January 21, 2013, at 266 US centers. After public
release of confidential interim data by the sponsor, the academic leadership of the study
recommended termination of the trial and the sponsor agreed.
INTERVENTIONS An Internet-based weight management programwas provided to all
participants. Participants were randomized to receive placebo (n=4454) or naltrexone,
32mg/d, and bupropion, 360mg/d (n=4456).
MAIN OUTCOMES ANDMEASURES Time from randomization to first confirmed occurrence of a
MACE. The primary analysis planned to assess a noninferiority hazard ratio (HR) of 1.4 after
378 expected events, with a confidential interim analysis after approximately 87 events (25%
interim analysis) to assess a noninferiority HR of 2.0 for consideration of regulatory approval.
RESULTS Among the 8910 participants randomized, mean age was 61.0 years (SD, 7.3 years),
54.5%were female, 32.1% had a history of cardiovascular disease, and 85.2% had diabetes,
with a median bodymass index of 36.6 (interquartile range, 33.1-40.9). For the 25% interim
analysis, MACE occurred in 59 placebo-treated patients (1.3%) and 35 naltrexone-bupropion–
treated patients (0.8%; HR, 0.59; 95% CI, 0.39-0.90). After 50% of planned events, MACE
occurred in 102 patients (2.3%) in the placebo group and 90 patients (2.0%) in the
naltrexone-bupropion group (HR, 0.88; adjusted 99.7% CI, 0.57-1.34). Adverse effects were
more common in the naltrexone-bupropion group, including gastrointestinal events in 14.2%
vs 1.9% (P < .001) and central nervous system symptoms in 5.1% vs 1.2% (P < .001).
CONCLUSIONS AND RELEVANCE Among overweight or obese patients at increased
cardiovascular risk, based on the interim analyses performed after 25% and 50% of planned
events, the upper limit of the 95% CI of the HR for MACE for naltrexone-bupropion
treatment, compared with placebo, did not exceed 2.0. However, because of the
unanticipated early termination of the trial, it is not possible to assess noninferiority for the
prespecified upper limit of 1.4. Accordingly, the cardiovascular safety of this treatment
remains uncertain and will require evaluation in a new adequately powered outcome trial.
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T he prevalence of obesity has increased steadily in theUnited States and globally over the last several de-cades, and this disorder is now considered one of the
most serious contemporary threats to cardiovascular health.1
The current obesity epidemic has resulted in a substantial in-
crease in the incidence of diabetes mellitus and related
complications.2 Lifestyle modification has long been consid-
ered a mainstay of therapy for obesity, but this intervention
hasproducedonlymodestweight loss andno reduction inma-
jor adverse cardiovascular events (MACE).3Accordingly, treat-
ment strategies have centered on pharmacological and surgi-
calapproaches toweight reduction.Drugtreatments forobesity
have yielded mixed results, with pharmacological agents
achievingmodestweight loss butwithoutdemonstrating a re-
duction in cardiovascular events. Two therapies, fenflur-
amine and sibutramine, were removed from themarket after
evidenceof cardiovascular harmemerged.4,5 Accordingly, the
medical community and regulatory authorities have ex-
pressed concerned about the cardiovascular safety of new
drugs to treat obesity.
The combination of naltrexone and bupropion reduced
weightduringphase3clinical trials,6 but theUSFoodandDrug
Administration (FDA) deferred approval based on safety con-
cerns related tosmall increases inbloodpressureandheart rate
in these trials.7 TheFDAmandated aplacebo-controlled, non-
inferiority cardiovascularoutcomes trial, specifying that an in-
terimanalysis after25%ofexpectedeventshadaccruedwould
need to rule out an upper 95% confidence interval of the haz-
ard ratio (HR) of 2.0 prior to approval and a HR of 1.4 at study
completion (potentially postapproval).8 Both the sponsor and
the FDA agreed to not disclose the 25% interim analysis until
completionof the study.While the trialwasongoing, the spon-
sor publicly released the confidential 25% interim results via
a patent publication.9 The study’s academic leadership rec-
ommended termination of the trial due to the breach of con-
fidentiality and the sponsor agreed. The current report pro-
vides results for the 50% interim data, which was the last
prespecified analysis performedby the datamonitoring com-
mittee prior to public disclosure. We also include the 25% in-
terimanalysis anda sensitivity analysis basedon the final data
available at last patient contact.
Methods
Study Design
The study was a phase 3b, multicenter, randomized, double-
blind,placebo-controlledtrial toassess theoccurrenceofMACE
inoverweightorobesepatientsat increased riskofadversecar-
diovascularoutcomes treatedwithanextended-release, fixed-
dose formulation containing a total daily dose of 32 mg of
naltrexone and 360 mg of bupropion. Interim monitoring
boundaries allowed for early termination for either superior
efficacy or established harm but not based on noninferiority
considerations.
The studyenrolledpatients intoadouble-blind lead-inpe-
riod to identify patients who did not tolerate treatment with
low-dosenaltrexone-bupropionorwhoexhibitedpoor adher-
ence. During the lead-in period, participants were randomly
assigned in a 1:1 ratio to 1 of 2 treatment sequences: 1 week of
activestudymedicationfollowedby1weekofplaceboor 1week
of placebo followedby 1week of active studymedication. Eli-
giblepatientsweresubsequently randomizedtotreatmentwith
eithernaltrexone-bupropionorplacebo in a 1:1 ratio (Figure 1).
Randomization occurred via an interactive voice recognition
systemusing a permuted block size of 4with no stratification
factors. To achieve the requisite number of events, the dura-
tion of randomized treatment was estimated to be between 2
and 4 years.
The trial required discontinuation from study medica-
tion at week 16 in a blinded manner for patients who did not
lose 2% or more of their initial body weight or experienced a
sustained (at ≥2 visits) increase in blood pressure (systolic or
diastolic) of 10 mmHg or greater. The approach was selected
in consultation with the FDA to avoid administration of
naltrexone-bupropion to patients who did not lose weight or
who experienced clinically unacceptable increases in blood
pressure as suggested in the labeling for bupropion.
Study Population
The study was approved by an institutional review board for
all study sites, and all enrolled patients provided written in-
formedconsent.Overweightorobesepatients at increased risk
of adverse cardiovascular outcomes were eligible to partici-
pate in the trial. The study requiredeligiblepatients tobeaged
50 years or older (women) or 45 years or older (men), have a
body mass index between 27 and 50 (calculated as weight in
kilograms divided by height in meters squared), and have a
waist circumference of 88 cm or more (women) or 102 cm or
more (men). Enrollment was restricted to patients with char-
acteristics associated with an increased risk of adverse car-
diovascular outcomes.
Several categories of increased risk were prespecified,
including documented preexisting cardiovascular disease.
Patients could also be enrolled if they demonstrated angina
with an abnormal graded exercise test result or exercise car-
diac imaging study (echocardiography or nuclear scintigra-
phy); an ankle brachial index of less than 0.9; or documented
50% or greater stenosis of a coronary, carotid, or lower
extremity artery. Patients with type 2 diabetes mellitus were
eligible if they had 2 or more of the following: hypertension,
dyslipidemia requiring pharmacotherapy, low high-density
lipoprotein cholesterol (<50 mg/dL [1.30 mmol/L] in women
or <40 mg/dL [1.04 mmol/L] in men), or current tobacco
smoking. Patients were required to have consistent access to
broadband Internet.
Patients were excluded for a myocardial infarction within
3 months prior to screening, severe angina pectoris,
New York Heart Association class 3 or 4 heart failure, or his-
tory of stroke or blood pressure of 145/95 mm Hg or higher.
Patients were also excluded for unstable weight within 3
months prior to screening (weight gain or loss of >3%),
planned bariatric or cardiac surgery, or percutaneous coro-
nary intervention. Other key exclusion criteria were severe
renal impairment (estimated glomerular filtration rate
<30 mL/min), elevated liver enzymes more than 3 times the
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Figure 1. Flow of Participants Through the Trial
2678 Excluded
1728 Did not meet eligibility criteria
201 History of tachyarrhythmia
656 Blood pressure ≥145/95 mm Hg
266 Not at increased risk of adverse cardiovascular outcomes
107 Body mass index ≤27 or ≥50
94 Long-term use or positive screen for opioids
404 Other reasons
95 Lost to follow-up
351 Did not give consent
2 Missing
418 Other reasons
78 Investigator decision
6 Study closed or terminated
1499 Did not complete lead-in period
543 Adverse events
425 Did not meet eligibility criteria
85 Recent drug/alcohol abuse or dependence within 6 mo prior to
screening or positive drug screen for cocaine, methamphetamine,
opiates, phencyclidine, or other prohibited drugs
187 Long-term use or positive screen for opioids
153 Other reasons
216 Withdrew consent
29 Sponsor decision
3 Missing
92 Other reasons
109 Protocol deviation
82 Lost to follow-up
105 Withdrew consent after completing lead-in period but prior to randomization
13 192 Patients screened
10 514 Entered lead-in period
9015 Completed lead-in period
8910 Randomized
4454 Randomized to receive placebo
4450 Received placebo as randomized
4 Did not receive placebo
4456 Randomized to receive naltrexone-bupropion
4455 Received naltrexone-bupropion as randomized
1 Did not receive naltrexone-bupropion
433 Discontinued from study
241 Lost to follow-up
192 Patient revoked contact with primary care physician or designated contact
410 Discontinued from study
217 Lost to follow-up
193 Patient revoked contact with primary care physician or designated contact
4450 Included in final efficacy analysis 4455 Included in final efficacy analysis
2124 Discontinued study drug during first 16 wk
1130 Did not meet wk 16 treatment continuation criteria
971 Weight change <2%
495 Patient decision to no longer receive study medication
259 Adverse events
 128 Lost to follow-up
19 Protocol deviation
14 Sponsor decision
4 Not treated
 75 Other reasons
3 Blood pressure change >10 mm Hg
12 Other reasons
144 Weight change <2% and blood pressure change >10 mm Hg
1903 Discontinued study drug during first 16 wk
993 Adverse events
367 Patient decision to no longer receive study medication
20 Blood pressure change >10 mm Hg
6 Other reasons
 125 Lost to follow-up
4 Protocol deviation
2 Sponsor decision
2 Unknown
1 Not treated
 64 Other reasons
267 Weight change <2%
52 Weight change <2% and blood pressure change >10 mm Hg
345 Did not meet wk 16 treatment continuation criteria
1618 Discontinued study drug during subsequent follow-up
678 Did not meet wk 16 treatment continuation criteria
586 Weight change <2%
602 Patient decision to no longer receive study medication
146 Adverse events
86 Lost to follow-up
15 Protocol deviation
14 Sponsor decision
1 Unknown
 76 Other reasons
14 Blood pressure change >10 mm Hg
9 Other reasons
69 Weight change <2% and blood pressure change >10 mm Hg
1437 Discontinued study drug during subsequent follow-up
577 Patient decision to no longer receive study medication
38 Blood pressure change >10 mm Hg
4 Other reasons
106 Lost to follow-up
18 Protocol deviation
17 Sponsor decision
3 Unknown
  111 Other reasons
203 Weight change <2%
44 Weight change <2% and blood pressure change >10 mm Hg
316 Adverse events
289 Did not meet wk 16 treatment continuation criteria
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upper limit of normal, long-term opioid use, history of sei-
zures or cranial trauma, mania, bulimia, anorexia nervosa,
acute depressive illness, or suicidality. Patients taking mono-
amine oxidase inhibitors within 14 days prior to screening
were excluded. Race/ethnicity was assessed by the investiga-
tor; this information was collected to determine if there were
differences in outcomes for patients with different racial or
ethnic backgrounds.
Treatments
All patients were encouraged to participate in an Internet-
based weight management program that included educa-
tional resources on healthy eating, exercise, and behavioral
modifications.Programinformationwaspresented in the form
ofweekly lessons that the studyparticipants could access on-
line, and they also received weekly emails with healthy life-
style tips and reminders. Patients also had access to a per-
sonalweight loss coach; programs to trackweight,meals, and
physical activity; and a low-fat, low-calorie meal plan.
Patients who discontinued study medication prema-
turely were encouraged to continue the weight management
program.The studymedication (naltrexone-bupropionorpla-
cebo) was provided in tablet form. Each active tablet con-
tained an extended-release formulation of 8 mg of naltrex-
one and 90 mg of bupropion or placebo. All tablets were
identical in appearance. Dose escalation occurred during the
first 4 weeks of treatment, beginning with 1 tablet daily dur-
ing the firstweek, increasing to 2 tablets duringweek 2, 3 tab-
letsduringweek3, and4 tabletsdailyduringweek4and there-
after. Dosage levels requiring more than 1 tablet daily were
administered twice per day (morning and evening).
OutcomeMeasures
A blinded independent clinical events committee at the
Cleveland Clinic Center for Clinical Research adjudicated
clinical outcomes, including cardiovascular death, nonfatal
myocardial infarction, nonfatal stroke, hospitalization for
unstable angina, and all-cause mortality. The prespecified
primary outcomemeasure was time from treatment random-
ization to the first confirmed occurrence of a MACE, defined
as cardiovascular death, nonfatal stroke, or nonfatal myocar-
dial infarction. The prespecified secondary outcomes were
times to first occurrence of MACE or hospitalization for
unstable angina, fatal or nonfatal stroke, and fatal or nonfatal
myocardial infarction. The incidence of coronary revascular-
ization was collected but not adjudicated. Additional out-
come measures included changes in body weight, body mass
index, and waist circumference. Although not prespecified in
the protocol, time-weighted changes in blood pressure and
heart rate over the course of the trial were assessed. Changes
were also determined after 16 weeks of treatment, when
adherence was relatively high, to assess the peak effects of
naltrexone-bupropion on these vital signs.
Statistical Analysis
Theprotocol specified enrollment of approximately 9880pa-
tients into the double-blind lead-in period,with the anticipa-
tion that 8900 would be randomized into the double-blind
treatment period. The primary analyses were performed for
the intention-to-treat (ITT)population,definedaspatientswho
underwent randomization into the treatmentperiodandwere
dispensed study medication. No imputation was performed
for missing data. Analyses were also performed for an “on-
treatment” population, defined as ITT patients who took at
least 1 dose of studymedication, with censoring of events oc-
curringmore than30days after apatient’s last confirmeddose
of study medication.
For the primary end point, 3 null hypotheses were pre-
specified: (1) that theHR for naltrexone-bupropion relative to
placebo is 2.0 or greater; (2) that the HR for naltrexone-
bupropion relative to placebo is 1.4 or greater; and (3) that the
HRfornaltrexone-bupropionrelative toplacebo is 1.0orgreater
(test for superiority). Estimatesof theHRsandassociated con-
fidence intervals comparing naltrexone-bupropion with pla-
cebowereobtainedusing theCoxproportionalhazardsmodel,
with randomized treatment as a covariate and the Kaplan-
Meiermethodused for time-to-event plots. Continuousmea-
surements of bodyweight and blood pressure over timewere
analyzedusing a general linearmodelwith treatment, cardio-
vascular risk group, race, and sex as factors andwith age and
baseline values as covariates. Categorical data were assessed
using the χ2 test.
An initial noninferiority analysis was planned after ac-
crual of approximately 87 events (25% interimanalysis) to de-
termine whether a 2-tailed upper bound of the 95% confi-
dence interval of the HR would rule out 2.0 (testing null
hypothesis 1), in which 1.31 was the least favorable HR point
estimate consistent with this noninferiority boundary. The
study designmandated that the 25% interim analysis be pro-
vided exclusively to a core team from the sponsor to enable
regulatory filing for approval, but all personnel involved in the
ongoing trial would remain blinded to these results. The FDA
agreed to keep the interim results confidential until the trial
was completed.
Sequentialmonitoring for superior efficacy or harm (test-
ing null hypothesis 3) was performed by the data monitoring
committeeusingO’Brien-Fleming group sequential boundar-
ies, implementedusingaLan-DeMetsαspending functionwith
planned interim analyses at 50% and 75% of event accrual.10
The primary analysis of the study would be formally ad-
dressedonly after accrual of 378 events (at study completion)
to determine whether an upper bound of the 95.6% confi-
dence interval of the HR would rule out 1.4 (testing null hy-
pothesis2), inwhich the least favorableHRpointestimatecon-
sistent with noninferiority was 1.14.
The study design did not allow prematurely stopping the
trial for achievement of the prespecified noninferiority crite-
rion (HR≤1.4) prior to study completion. The50% interimand
final results were analyzed using 99.7% confidence intervals
basedon theprespecified α spending function for testing null
hypothesis 3 after 192 adjudicated MACE.10 The 25% interim
results were analyzed using the 95% confidence intervals as
prespecified in theprotocol (Supplement) andstatistical analy-
sis plan. As a sensitivity analysis, MACE outcomes were also
reported at the time of last patient contact (after approxi-
mately 64% of planned events had accrued). No P values for
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noninferiority are reported because these cannot be appro-
priately adjusted for data derived from interim analyses not
intended to serveas evidence for achievementof theprespeci-
fiedcriterionfornoninferiority.All statisticalanalyseswereper-
formed using SAS software, version 9.3 (SAS Institute Inc).
Sample Size Determination
The trial was designed to provide 90% power to rule out the
1.4margin (ie, theupper limit of the confidence intervalwould
not exceed 1.4) when the true HR is 1.0, which required 378
primary events. The early preapproval analysis to rule out the
2.0margin required 87 primary events to provide 90%power
when the trueHR is 1.0. In both settings, a 1-sided type I error
(α) of 2.5% was used. To obtain sample sizes, an annualized
rate of primary events of 1.5% in the placebo group was as-
sumed. The recruitment was assumed to take 1.5 years, with
maximum patient follow-up of 4 years. It was assumed that
7% of the study population would discontinue during the
lead-in period, with a loss–to–follow-up rate of 1.2% annu-
ally. Under these assumptions, the trial required 3448partici-
pants per treatment group.However, the studyplanned to re-
cruit 4450 per treatment group to compensate for any
deviations from the anticipated event rate or recruitment or
retention rates.
Early Data Release and Study Termination
The study’s academic executive steering committee, data
monitoring committee, and sponsor at the time (Orexigen
Therapeutics) developed a data access plan specifying strict
confidentiality of interim data to be used in a regulatory filing
for drug approval. The data monitoring committee released
interim data to the sponsor after approximately 25% of
planned events had accrued in November 2013, and the
blinded trial continued as planned. On September 10, 2014,
the FDA approved naltrexone-bupropion for marketing but
publicly stated that the number of individuals who had
received knowledge of the interim results, both inside and
outside the company, was far greater than the agency consid-
ered essential to facilitate the regulatory submission for
approval.11 The FDA also stated that due to the breach of con-
fidentiality, the trial could not be used to meet the postap-
proval requirement to rule out a noninferiority margin of
1.4.11 Nonetheless, the FDA encouraged the sponsor to con-
tinue the trial as originally planned.
In March 2015, while the trial was still ongoing (after
sponsorship was transferred to Takeda Pharmaceuticals),
Orexigen publicly released the 25% interim results via a pat-
ent publication and submission to the Securities and Ex-
changeCommission.9Thepublishedpatent claimedamethod
for reducing cardiovascular risk and included the 25% in-
terimdata forMACE showing an estimatedHRof 0.59,which
was reported in themedia as evidenceof a cardiovascular ben-
efit for naltrexone-bupropion.12
Theexecutive steering committee concluded that thepre-
mature release of interim data had compromised the scien-
tific integrity of the ongoing study, precluding successful
completion. The executive steering committee recom-
mended trial termination on May 12, 2015, and the original
sponsor (OrexigenTherapeutics) and the currentholder of the
Investigational New Drug application (Takeda Pharmaceuti-
cals) agreed. The executive steering committee also decided
to unblind and partially release outcome data from a recently
completed,preplanned50%interimanalysis to correct the im-
pression of benefit created by release of potentially unreli-
able 25% interimdata.13 The executive steering committee ex-
pressed concern that the breach of confidentiality through
release of preliminary data could result in inappropriate use
of naltrexone-bupropionwith an expectation of cardiovascu-
lar benefit.
The50%interimanalysiswascompletedonMarch3,2015,
based on 192 adjudicatedMACE (from a database lock on Feb-
ruary 3, 2015). As a result of the termination of the study, the
preplanned 50% interim analysiswas considered themost ap-
propriate analysis to generate the primary results. Additional
outcomes accumulated after the February 2015 database lock
are included in a sensitivity analysis, which reports results af-
ter64%ofplannedevents.The25%interimanalysisused in the
regulatory approval of naltrexone-bupropion is also reported.
Results
Patients
Thedispositionof patients is shown inFigure 1. FromJune 13,
2012, until January 21, 2013, the trial screened 13 192 patients
andrandomized10514 into the lead-inperiod, and10505were
included in the enrolled population (9 patients did not re-
ceive studymedication), with 9015 patients (85.8%) success-
fully completing thisphase.Themost commonreason fornon-
completion during the lead-in was an adverse event, which
occurred in543patients (5.2%).Ultimately,8910patientswere
randomized into theongoing study,with8905 included in the
ITT population (5 did not receive study medication).
The baseline characteristics of the patients are shown in
Table 1. Themean age of randomized patients was 61.0 years
(SD, 7.3 years),with a slight predominanceofwomen (54.5%),
and83.5%patientsweredescribedaswhite. Themedianbody
mass indexwas36.6 (interquartile range [IQR], 33.1-40.9),with
amedianbodyweight of 104.1 kg (IQR,92.1-118.1 kg) andame-
dian waist circumference of 118.1 cm (IQR, 110-128 cm). Type
2 diabetes was present in 85.2% of patients, established car-
diovascular disease in 32.1%, andbothdisorders in 17.4%.Car-
diovascular risk factorswerewell controlled,with amean sys-
tolicbloodpressureof 125.7mmHg(SD, 12.5mmHg), amedian
low-density lipoprotein cholesterol level of 82.0 mg/dL
(2.12mmol/L) (IQR, 65-106mg/dL [1.68-2.75mmol/L]), and a
median high-density lipoprotein cholesterol level of 45.0
mg/dL (1.17 mmol/L) (IQR, 38-53 mg/dL [0.98-1.37 mmol/L]).
Concomitant medications included statins in 79.2% of pa-
tients, antihypertensive medications in 92.0%, and glucose-
lowering agents in 75.1%.
Efficacy Outcomes
Primary End Point
Table 2 shows theprimary and secondary cardiovascular out-
comes for the ITTpopulation at the 50% interimanalysis. The
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primary prespecified outcome measure, time to first MACE,
occurred in 192 patients, 102 (2.3%) in the placebo group and
90(2.0%) in thenaltrexone-bupropiongroup (HR,0.88;99.7%
CI, 0.57-1.34). The components of theprimary composite out-
come included cardiovascular death in 34placebo-treatedpa-
tients (0.8%) and 17 naltrexone-bupropion–treated patients
(0.4%; HR, 0.50; 99.7% CI, 0.21-1.19). Nonfatal stroke oc-
curred in 19patients (0.4%) in theplacebogroupand21 (0.5%)
in the naltrexone-bupropion group (HR, 1.10; 99.7%CI, 0.44-
2.78). Nonfatal myocardial infarction occurred in 54 patients
(1.2%) in the placebo group and 54 (1.2%) in the naltrexone-
bupropion group (HR, 1.00; 99.7% CI, 0.57-1.75). Figure 2A
shows theKaplan-Meier plot of time to firstMACE for the 50%
interim analysis.
Table 3 shows results of the sensitivity analysis based on
the final end-of-study assessment for the primary and sec-
ondary cardiovascular outcomes in the ITT population. The
primaryoutcomemeasure, time to firstMACE,occurred in 124
patients (2.8%) in the placebo treatment group and 119 pa-
tients (2.7%) in the naltrexone-bupropion group (HR, 0.95;
99.7%CI,0.65-1.38). The components of theprimary compos-
ite outcome showed cardiovascular death in 42 placebo-
treated patients (0.9%) and 26 naltrexone-bupropion–
treatedpatients (0.6%;HR,0.61;99.7%CI,0.30-1.27).Nonfatal
stroke occurred in 21 patients (0.5%) in theplacebo group and
28 (0.6%) in thenaltrexone-bupropiongroup (HR, 1.32; 99.7%
CI, 0.57-3.08). Nonfatal myocardial infarction occurred in 67
patients (1.5%) in the placebo group and 68 (1.5%) in the nal-
trexone-bupropion group (HR, 1.01; 99.7% CI, 0.61-1.66).
Figure 2B shows the Kaplan-Meier plot of time to first MACE
for the final end-of-study analysis.
Table 4 shows the results from the 25% interim analysis
used in the regulatory approval of naltrexone-bupropion and
subsequently released by the original sponsor (Orexigen) in a
patent filing. The primary outcome, time to first MACE, oc-
curred in 59 patients (1.3%) in the placebo group and 35 pa-
tients (0.8%) inthenaltrexone-bupropiongroup(HR,0.59;95%
CI, 0.39-0.90). Table 4 also shows events rates and HRs with
95%confidence intervals for components of the primary out-
come and secondary outcomes for the 25% interim analysis.
The 25% interim analysis shows 95% confidence intervals
rather than 99.7% confidence intervals because this analysis
tested only whether the trial ruled out a noninferiority mar-
gin of 2.0 and did not test for the margin of 1.4. Table 4 also
shows the primary end point and its components for the on-
treatment analysis. For theon-treatment analyses, theHRsare
less favorable than the ITT analyses and show wider confi-
dence intervals.
Secondary Outcomes
Table 2 shows the secondary outcome measures for the ITT
populationat the50%interimanalysis.ThecompositeofMACE
plus hospitalization for unstable angina occurred in 142 pla-
cebopatients (3.2%)and133naltrexone-bupropion–treatedpa-
tients (3.0%;HR,0.93;99.7%CI,0.66-1.33).Table3showsthese
same outcomes at study completion and Table 4 shows these
outcomesfor the25%interimanalysis.Resultsatstudycomple-
tion (64% of planned events) were less favorable than ob-
served at the 50% interim analysis (HR, 0.95; 99.7% CI, 0.95-
1.38). The 25% interim analysis showed more favorable HRs
than subsequent analyses, with very wide confidence inter-
vals due to the low number of events. Table 2, Table 3, and
Table 1. Demographics and Baseline Characteristics of the
Intention-to-Treat Population
Characteristics
Placebo
(n = 4450)
Naltrexone-
Bupropion
(n = 4455)
Demographics and laboratory
characteristics
Age, mean (SD), y 60.9 (7.38) 61.1 (7.27)
Female, No. (%) 2419 (54.4) 2437 (54.7)
White, No. (%) 3698 (83.1) 3738 (83.9)
Blood pressure,
mean (SD),
mm Hg
Systolic 125.5 (12.6) 125.9 (12.5)
Diastolic 74.4 (9.1) 74.5 (9.0)
Weight, mean (SD), kg 106.3 (19.2) 105.6 (19.1)
Body mass index,
median (IQR)a
36.7 (33.1-41.1) 36.6 (33.1-40.8)
Waist circumference,
median (IQR), cm
118.5 (110-128) 118.0 (110-128)
Glycohemoglobin level
in patients with diabetes,
median (IQR), %
7.1 (6.4-8.2) 7.0 (6.1-8.1)
Cholesterol,
median (IQR), mg/dL
Low-density lipoprotein 82.0 (65-106) 82.0 (64-105)
High-density lipoprotein 45.0 (38-54) 45.0 (37-53)
Triglycerides,
median (IQR), mg/dL
166.0 (120-230) 166.0 (119-232)
High-sensitivity
C-reactive protein,
median (IQR), mg/L
2.9 (1.4-5.9) 2.9 (1.4-5.9)
Cardiovascular risk factors,
No. (%)
Cardiovascular disease 1447 (32.5) 1415 (31.8)
Type 2 diabetes mellitus 3803 (85.5) 3784 (84.9)
Duration of type 2
diabetes mellitus,
median (IQR), y
7.6 (3.8-12.9) 7.8 (3.9-12.9)
Cardiovascular disease
and type 2 diabetes mellitus
801 (18.0) 745 (16.7)
Current smoker 416 (9.3) 405 (9.1)
Hypertension 4117 (92.5) 4162 (93.4)
Dyslipidemia 4070 (91.5) 4100 (92.0)
Medications, No. (%)
Statin 3518 (79.1) 3534 (79.3)
Insulin 1038 (23.3) 1038 (23.3)
Metformin 2543 (57.1) 2525 (56.7)
β-Blocker 1705 (38.3) 1768 (39.7)
Diuretic 1413 (31.8) 1470 (33.0)
ACE inhibitor or ARB 3407 (76.6) 3440 (77.2)
Calcium channel blocker 845 (19.0) 905 (20.3)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blocker; IQR, interquartile range.
SI conversions: To convert low- and high-density lipoprotein cholesterol to
millimoles per liter, multiply by 0.0259. To convert triglycerides to millimoles
per liter, multiply by 0.0113.
a Calculated as weight in kilograms divided by height in meters squared.
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Table 4 also show the additional secondary outcomes of fatal
or nonfatal stroke and fatal or nonfatal myocardial infarction
for the 50% interim analysis, end-of-study analysis, and 25%
interim analysis, respectively.
Other Cardiovascular Outcomes
Table 2 and Table 3 show other cardiovascular outcomes
including all-cause mortality, coronary revascularization,
hospitalization for unstable angina, and additional composite
Figure 2. Time toMACE in the 50% Interim Analysis and the Final End-of-Study Analysis
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Table 2. Primary and Secondary Efficacy Outcomes (50% Interim Analysis)
End Points
Placebo, No. (%)
(n = 4450)
Naltrexone-Bupropion,
No. (%)
(n = 4455)
Hazard Ratio
(99.7% CI)a
Intention-to-treat analysis
Primary outcome
Major adverse cardiovascular events 102 (2.3) 90 (2.0) 0.88 (0.57-1.34)
Components of the primary outcome
Cardiovascular death 34 (0.8) 17 (0.4) 0.50 (0.21-1.19)
Nonfatal stroke 19 (0.4) 21 (0.5) 1.10 (0.44-2.78)
Nonfatal myocardial infarction 54 (1.2) 54 (1.2) 1.00 (0.57-1.75)
Secondary outcomes
Major adverse cardiovascular events +
hospitalization for unstable angina
142 (3.2) 133 (3.0) 0.93 (0.66-1.33)
Fatal or nonfatal stroke 21 (0.5) 22 (0.5) 1.04 (0.43-2.55)
Fatal or nonfatal myocardial infarction 57 (1.3) 55 (1.2) 0.96 (0.55-1.67)
Other outcomes
All-cause mortality 51 (1.1) 43 (1.0) 0.84 (0.46-1.54)
Hospitalization for unstable angina 43 (1.0) 47 (1.1) 1.09 (0.59-2.02)
Coronary revascularization 145 (3.3) 132 (3.0) 0.91 (0.64-1.29)
All-cause mortality plus nonfatal
myocardial infarction + nonfatal stroke
119 (2.7) 114 (2.6) 0.95 (0.65-1.40)
Major adverse cardiovascular events +
hospitalization for unstable angina +
coronary revascularization
205 (4.6) 188 (4.2) 0.91 (0.68-1.23)
On-treatment analysis
Major adverse cardiovascular events 37 (0.8) 43 (1.0) 0.97 (0.50-1.88)
Components of the primary outcome
Cardiovascular death 10 (0.2) 8 (0.2) 0.67 (0.17-2.72)
Nonfatal stroke 7 (0.2) 11 (0.2) 1.25 (0.30-5.18)
Nonfatal myocardial infarction 21 (0.5) 24 (0.5) 0.96 (0.40-2.3)
a Based on Cox proportional hazards
model with treatment as a factor;
adjusted 99.7% CIs based on group
sequential design.
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end points at the 50% interim and final end-of-study analy-
sis. At the 50% interim analysis, all-cause mortality occurred
in 51 placebo patients (1.1%) and 43 naltrexone-bupropion
patients (1.0%; HR, 0.84; 99.7% CI, 0.46-1.54). Hospitaliza-
tion for unstable angina occurred in 43 (1.0%) of placebo-
treated patients and 47 (1.1%) of naltrexone-bupropion–
treated patients (HR, 1.09; 99.7% CI, 0.59-2.02). Coronary
revascularization occurred in 145 (3.3%) of placebo patients
and 132 (3.0%) of naltrexone-bupropion patients (HR, 0.91;
99.7% CI, 0.64-1.29).
Table 2 and Table 3 also include the post hoc composite
outcome of all-cause mortality, nonfatal myocardial infarc-
tion, and nonfatal stroke, which showed less favorable HRs
than the primary outcome because the fewer cardiovascular
deaths were counterbalanced by an excess of noncardiovas-
cular mortality. The broadest measure of cardiovascular out-
come,MACEplus hospitalization for unstable angina or coro-
nary revascularization,occurred in205placebopatients (4.6%)
and188naltrexone-bupropionpatients (4.2%;HR,0.91; 99.7%
CI, 0.68-1.23). Table 2, Table 3, and Table 4 also show the pri-
mary end point and components of the primary end point for
theon-treatmentanalysis.Becauseof the lowadherence rates,
these analyses have fewer patient-years of follow-up, result-
ing in wider confidence intervals, and consistently show less
favorable HRs than the ITT population.
Adherence and Retention
Figure 3 shows time to permanent study drug discontinua-
tion for any reason. Adherence to study drug, as expected,
was relatively low and showed a different pattern between
the 2 treatment groups. After the first 2 weeks of treatment,
95.1% of patients treated with naltrexone-bupropion and
(97.6%) of placebo patients were taking study medication. At
16 weeks, 72.1% of placebo-treated patients and 64.0% of
naltrexone-bupropion–treated patients were still taking
study drug (P < .001). One year after randomization, 26.3% of
placebo patients and 37.5% of naltrexone-bupropion patients
were still taking study drug (P < .001). Two years after ran-
domization, only 17.3% of placebo patients and 27.0% of
naltrexone-bupropion patients were still taking study drug
(P < .001). The median duration of treatment was 16.3 weeks
for placebo (IQR, 15.6-53.1 weeks) and 18.4 weeks for
naltrexone-bupropion (IQR, 8.1-109.3 weeks).
A largedecrease in thenumber of patients receiving study
drug occurred after the 16-week assessment,with 44%of pla-
cebopatients and 17.8%ofnaltrexone-bupropionpatientsdis-
continued by investigators. Most discontinuations were due
to a failure to lose 2% of body weight, but 230 placebo pa-
tients and 154 naltrexone-bupropion patients discontinued
treatmentbecauseofagreater than10–mmHgincrease inblood
pressure (Figure 1). Ahighpercentage of patientswhodiscon-
Table 3. Primary and Secondary Efficacy Outcomes (Final End-of-Study Analysis)
End Points
Placebo, No. (%)
(n = 4450)
Naltrexone-Bupropion,
No. (%)
(n = 4455)
Hazard Ratio
(99.7% CI)a
Intention-to-treat analysis
Primary outcome
Major adverse cardiovascular events 124 (2.8) 119 (2.7) 0.95 (0.65-1.38)
Components of the primary outcome
Cardiovascular death 42 (0.9) 26 (0.6) 0.61 (0.30-1.27)
Nonfatal stroke 21 (0.5) 28 (0.6) 1.32 (0.57-3.08)
Nonfatal myocardial infarction 67 (1.5) 68 (1.5) 1.01 (0.61-1.66)
Secondary outcomes
Major adverse cardiovascular events +
hospitalization for unstable angina
171 (3.8) 164 (3.7) 0.95 (0.69-1.31)
Fatal or nonfatal stroke 23 (0.5) 31 (0.7) 1.34 (0.60-2.99)
Fatal or nonfatal myocardial infarction 71 (1.6) 69 (1.5) 0.96 (0.59-1.58)
Other outcomes
All-cause mortality 71 (1.6) 65 (1.5) 0.91 (0.55-1.50)
Hospitalization for unstable angina 50 (1.1) 51 (1.1) 1.01 (0.57-1.82)
Coronary revascularization 170 (3.8) 152 (3.4) 0.89 (0.64-1.23)
All-cause mortality + nonfatal myocardial
infarction + nonfatal stroke
151 (3.4) 156 (3.5) 1.02 (0.73-1.43)
Major adverse cardiovascular events +
hospitalization for unstable angina +
coronary revascularization
244 (5.5) 226 (5.1) 0.92 (0.70-1.20)
On-treatment analysis
Major adverse cardiovascular events 39 (0.9) 47 (1.1) 0.99 (0.52-1.87)
Components of the primary outcome
Cardiovascular death 11 (0.2) 9 (0.2) 0.67 (0.18-2.54)
Nonfatal stroke 7 (0.2) 12 (0.3) 1.35 (0.33-5.47)
Nonfatal myocardial infarction 22 (0.5) 26 (0.6) 0.98 (0.42-2.30)
a Based on Cox proportional hazards
model with treatment as a factor;
adjusted 99.7% CIs based on group
sequential design.
Naltrexone-Bupropion Treatment andMACE in Overweight and Obese Patients Original Investigation Research
jama.com (Reprinted) JAMA March 8, 2016 Volume 315, Number 10 997
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
tinued treatment remained in follow-up for MACE and con-
tributed to the ITT analysis. Discontinuation of follow-up oc-
curred in 9.7% of placebo patients and 9.2% of naltrexone-
bupropion patients. The median duration of follow-up was
121 weeks (IQR, 114-128 weeks) for placebo and 121 weeks
(IQR, 114-128 weeks) for naltrexone-bupropion.
Other OutcomeMeasures
At trial completion, body weight decreased a mean of 3.9 kg
(95% CI, −4.1 to −3.7 kg) in the naltrexone-bupropion group
and 1.2 kg (95% CI, −1.3 to −1.0 kg) in the placebo group, cor-
responding to reductions of 3.6% and 1.1%, respectively
(P < .001). The between-group mean difference was 2.7 kg
(95% CI, −2.9 to −2.5 kg; P < .001), representing a 2.5% reduc-
tion (95% CI, −2.8% to −2.3%) in body weight. At trial
completion, waist circumference decreased 2.1 cm (95% CI,
−2.4 to −1.8 cm) in the naltrexone-bupropion group and
0.8 cm (95% CI, −1.0 to −0.5 cm) in the placebo group
(P < .001). In post hoc analysis of data at 16 weeks, time-
weighted systolic blood pressure increased a mean of
1.4 mm Hg (95% CI, 1.0-1.7 mm Hg) in the naltrexone-
bupropion group and 0.5 mm Hg (95% CI, 0.4-0.6 mm Hg) in
the placebo group (P < .001). Time-weighted average heart
rate increased 0.7/min (95% CI, 0.5/min to 0.9/min) in the
naltrexone-bupropion group and 0.6/min (95% CI, 0.3/min to
0.8/min) in the placebo group. The increase in blood pressure
and heart rate at approximately 16 weeks, when adherence to
treatment was still relatively high, showed a mean difference
in blood pressure between treatment groups of 0.46 mm Hg
(95% CI, 0.01-0.92 mm Hg) and a mean difference in heart
rate of 0.45/min (95% CI, 0.11/min to 0.78/min). Plots of
change over time in body weight, systolic blood pressure,
and heart rate are shown in Figure 4, and Figure 5.
Figure 3. Time FromRandomization to Permanent Study Drug
Discontinuation
100
80
60
40
20
0
4455
4450
26
2052
1465
16
2752
2914
52
1661
1163
78
1394
942
104
1196
765
130
231
130
St
ud
y 
Dr
ug
 D
is
co
nt
in
ua
tio
n,
 %
Weeks Following Randomization
No. at risk
Placebo
Placebo
Naltrexone-
bupropion
Naltrexone-bupropion
0
Table 4. Efficacy Outcomes (25% Interim Analysis)
End Points
Placebo, No. (%)
(n = 4450)
Naltrexone-Bupropion,
No. (%)
(n = 4455)
Hazard Ratio
(95% CI)a
Intention-to-treat analysis
Primary outcome
Major adverse cardiovascular events 59 (1.3) 35 (0.8) 0.59 (0.39-0.90)
Components of the primary outcome
Cardiovascular death 19 (0.4) 5 (0.1) 0.26 (0.10-0.70)
Nonfatal stroke 10 (0.2) 7 (0.2) 0.70 (0.27-1.83)
Nonfatal myocardial infarction 33 (0.7) 23 (0.5) 0.70 (0.41-1.18)
Secondary outcomes
Major adverse cardiovascular events +
hospitalization for unstable angina
79 (1.8) 63 (1.4) 0.80 (0.57-1.11)
Fatal or nonfatal stroke 11 (0.2) 7 (0.2) 0.63 (0.25-1.64)
Fatal or nonfatal myocardial infarction 34 (0.8) 24 (0.5) 0.70 (0.42-1.19)
Other outcomes
All-cause mortality 22 (0.5) 10 (0.2) 0.45 (0.22-0.96)
Hospitalization for unstable angina 23 (0.5) 29 (0.7) 1.26 (0.73-2.18)
Coronary revascularization 65 (1.5) 65 (1.5) 1.00 (0.71-1.41)
All-cause mortality + nonfatal myocardial
infarction + nonfatal stroke
62 (1.4) 40 (0.9) 0.64 (0.43-0.96)
Major adverse cardiovascular events +
hospitalization for unstable angina +
coronary revascularization
105 (2.4) 91 (2.0) 0.87 (0.65-1.15)
On-treatment analysis
Major adverse cardiovascular events 30 (0.7) 23 (0.5) 0.71 (0.41-1.22)
Components of the primary outcome
Cardiovascular death 7 (0.2) 4 (0.1) 0.57 (0.16-1.94)
Nonfatal stroke 7 (0.2) 6 (0.1) 0.72 (0.24-2.16)
Nonfatal myocardial infarction 16 (0.4) 13 (0.3) 0.77 (0.37-1.60)
a Based on Cox proportional hazards
model with treatment as a factor.
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Adverse Events
Themost common adverse events leading to the discontinu-
ation of study drug are shown in Table 5. These included gas-
trointestinal adverse effects, which occurred in 14.2% of
naltrexone-bupropion–treated patients and 1.9% of placebo-
treated participants (P < .001), and central nervous system
symptoms, which occurred in 5.1% of naltrexone-bupropion
patients and 1.2% of placebo patients (P < .001). Psychiatric
symptoms resulted in study drug discontinuation in 3.1% of
naltrexone-bupropion patients and 0.9% of placebo patients
(P < .001).
Discussion
The cardiovascular safety of obesity drugs has received con-
siderableattentionafter thewithdrawalofsibutramineandfen-
fluramine by the FDA for cardiovascular harm.4,5 Somedrugs
that reduce appetite are sympathomimetic agents that can in-
creasebloodpressureandheart rate.Bupropion, adrugwidely
used to treat depression, has anorexigenic properties result-
ing in modest weight loss.14 The effectiveness of bupropion
is increased when combined with the opioid antagonist
naltrexone.15 A combination product was considered by the
FDAforapproval,but theagency initially rejectedthisnewdrug
application because of elevation of blood pressure and heart
rate, requiring a preapproval cardiovascular safety study.
Our study was designed to provide an assessment of car-
diovascular outcomes for extended-release naltrexone,
32 mg/d, and bupropion, 360 mg/d. However, the study was
terminated prematurely after the unplanned release of an
interim analysis after 25% of planned events with MACE oc-
curring in59placebo-treatedpatients (1.3%)and35naltrexone-
bupropion–treated patients (0.8%; HR, 0.59; 95% CI, 0.39-
0.90). After 50% of planned events, outcomes were less
favorable, with MACE occurring in 102 patients (2.3%) in the
placebo group and 90 patients (2.0%) in the naltrexone-
bupropion group (HR, 0.88; adjusted 99.7% CI, 0.57-1.34).
Given the unplanned early termination of the trial, which di-
rectly resulted from the inappropriate release of thehighly fa-
vorable 25% interimdata, these findingsdonot establishnon-
inferiority for the prespecified margin of 1.4.
Recently, theFDAhas adopted a 2-stage approach todrug
approval with the intent of ruling out a high degree of hazard
prior to approval based on an interim analysis of preliminary
clinical trial results. These trials then continue to potentially
rule out amore stringent noninferioritymargin in the postap-
proval setting.16Theapproachofa2-stagesafety trialwasorigi-
nally developed to facilitate safety assessment of diabetes
drugs.16 For naltrexone-bupropion, theFDA required that the
sponsorconductanoninferioritycardiovascularoutcomestrial,
specifying that an interim analysis would need to rule out a
noninferioritymargin of 2.0 prior to approval and amargin of
1.4 at study completion (potentially postapproval).
Figure 4. Change in BodyWeight During the Trial
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Figure 5. Changes in Systolic Blood Pressure and Heart Rate During the Trial
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The success of the 2-stage approach to drug develop-
ment relies on the maintenance of strict confidentiality dur-
ing the time from submission of the initial interim results un-
til completion of the definitive safety study. In practice, a
defined team from the trial sponsor is provided with the in-
terim results and submits thedrug for approval but hasnoon-
going involvementwith thestudy.Thecompanybusiness lead-
ership, the study’s academic leadership, and all other study
personnel remain blinded until the definitive study is com-
pleted.TheFDAalsoagreed tomaintain confidentiality for the
25% interim data until the trial was completed.
During our trial, publication of a patent submitted by
Orexigen, along with a subsequent submission by the com-
pany to the Securities and Exchange Commission,9 resulted
in public release of the 25% interim results of the trial. The
published patent claimed a method of reducing cardiovascu-
lar risk based on a 41% reduction in cardiovascular risk with
naltrexone-bupropion, which were interpreted in the media
as showing cardiovascular benefit. The study academic lead-
ership subsequently recommended and the sponsors agreed
to terminate the trial.
As a result of these events, interpretation of the results of
the trial involves complex statistical issues. Noninferiority
testing to rule out a doubling of cardiovascular risk (an upper
95% confidence limit of the HR not exceeding 2.0) was suc-
cessfully completed after accrual of 94 (25%) of the planned
378 events (Table 4). Accordingly, it is possible to conclude
that naltrexone-bupropion does not double cardiovascular
risk based on the preplanned 25% interim analysis, but it is
not possible to draw any conclusions related to the noninferi-
ority margin of 1.4. A new cardiovascular outcome trial will
be required to address the regulatory mandate to rule out
a noninferiority margin of 1.4 but will not be available for a
minimum of 3 to 4 years.
Per the study design, the data monitoring committee
could consider stopping the trial for overwhelming evidence
of efficacy or harm based on interim analyses at 50% and
75% of trial completion with statistical adjustments using
O’Brien-Fleming boundaries. The study design did not allow
early termination for demonstration of noninferiority. The
primary outcome data reported in this manuscript were
determined using the 50% interim analysis (192 events), the
last preplanned analysis performed prior to termination of
the trial. The HRs along with the 99.7% confidence intervals
reflect the appropriate statistical adjustments for the 50%
interim analysis. No P values for either superiority or nonin-
feriority are reported because the results of the prematurely
terminated trial cannot be used to rigorously address either
superiority or the prespecified noninferiority margin of 1.4.
An additional sensitivity analysis was performed using the
final data available at the time of last patient contact and
showed less favorable findings than the primary analysis.
The final data include 243 primary composite end points,
approximately 64% of the intended 378 events.
In clinical trials, an ITT analysis is preferred because it is
the only analysis that preserves the integrity of randomiza-
tion and represents a conservative approach to assessment of
efficacy.However, ina safety study,particularlyonewitha low
adherence rate, the on-treatment analysis can provide addi-
tional insightbecause it reflectsoutcomes inpatientswhile they
were actually taking the medication under study. In a safety
study, when adherence rates are low, the ITT analysis can re-
sult in a false-positive declaration of noninferiority. Accord-
ingly, an on-treatment analysis is essential to confirm find-
ings derived from the ITT analysis.
In our trial, the on-treatment analysis shows HRs that are
less favorable (higher) than the ITT analysis for naltrexone-
bupropion. This finding is particularly evident for the 25%
Table 5. Most CommonAdverse Effects Leading to Discontinuation of Study Drug
Adverse Effects
Placebo, No. (%)
(n = 4450)
Naltrexone-Bupropion, No. (%)
(n = 4455) P Valuea
Any adverse effect 388 (8.7) 1253 (28.1) <.001
Gastrointestinal 84 (1.9) 631 (14.2) <.001
Nausea 21 (0.5) 333 (7.5) <.001
Constipation 15 (0.3) 123 (2.8) <.001
Vomiting 1 (<0.1) 87 (2.0) <.001
Central nervous system 52 (1.2) 226 (5.1) <.001
Tremor 0 77 (1.7) <.001
Dizziness 7 (0.2) 62 (1.4) <.001
Headache 14 (0.3) 51 (1.1) <.001
Psychiatric disorders 39 (0.9) 136 (3.1) <.001
Insomnia 16 (0.4) 35 (0.8) .01
Anxiety 8 (0.2) 26 (0.6) .002
Hallucinations 0 11 (0.2) <.001
Depression 9 (0.2) 5 (0.1) .28
Increased blood pressure 23 (0.5) 39 (0.9) .04
Palpitations 5 (0.1) 19 (0.4) .004
Feeling jittery 1 (<0.1) 15 (0.3) <.001
Flushing or hot flashes 2 (<0.1) 13 (0.3) .004
Fatigue 1 (<0.1) 12 (0.3) .002 a By 2-sided χ2 test.
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interim analysis showing 24 more primary events for the pla-
cebo vs naltrexone-bupropion treatment group in the ITT
analysis (59 vs 35) but only 7 excess events in the placebo
group for the on-treatment analysis (30 vs 23) (Table 4).
The most favorable component of the primary end point at
the 25% interim analysis, cardiovascular death, 19 events
for placebo vs 5 for naltrexone-bupropion, was driven
almost exclusively by a 12-to-1 imbalance in death favoring
naltrexone-bupropion among patients who were no longer
taking study drug. These observations suggest that any infer-
ence regarding noninferiority must be viewed cautiously
pending completion of an adequately powered new clinical
trial, preferably with greater adherence to treatment.
The trial offers some useful findings with respect to the
effectiveness of naltrexone-bupropion as a treatment for obe-
sity andprovides insights about the conduct of future trials of
obesity treatments. For the ITT population, at trial comple-
tion, the observed weight loss with naltrexone-bupropion
wasmodest, with amean reduction of 3.9 kg (95% CI, −4.1 to
−3.7 kg), 3.6% of initial body weight, compared with 1.2 kg
(95%CI, −1.3 to −1.0 kg) in the placebo group (Figure 4). Com-
paredwith placebo, the incrementalweight losswas approxi-
mately 2.7 kg (95%CI, −2.9 to−2.5 kg), or 2.5%ofbodyweight.
The modest weight loss efficacy was likely related to low ad-
herence to treatment,with approximately 63%ofnaltrexone-
bupropion patients and 74% of placebo patients no longer
taking study drug after 12 months.
A relatively low adherence rate was anticipated in the
design of the trial. Patients were discontinued from treat-
ment at 16 weeks (but remained in the ITT population) if they
lost less than 2% of initial body weight, an approach selected
by the FDA, sponsor, and academic leadership to reflect the
use of antiobesity agents in clinical practice. Patients and
physicians do not persist with an obesity treatment in the
absence of weight loss. Patients with obesity are often dispir-
ited and easily frustrated by their inability to lose weight per-
manently after years of trying.17,18 These experiences may
contribute to suboptimal adherence to treatment recommen-
dations and poor study retention. Despite maximal efforts,
poor adherence andmodest retention represent challenges to
the conduct of such trials. Because cardiovascular outcomes
trials typically require many patient-years of exposure, suc-
cessfully completing such trials will require intensive efforts
to promote adherence to study drugs and retention of
patients in the trial. The low adherence rate and early termi-
nation of our trial does not allow any reliable conclusions
about the long-term safety of naltrexone-bupropion.
Because blood pressure and heart rate increases repre-
sented the major reasons for concern about the cardiovascu-
lar safety of naltrexone-bupropion, we collected these vital
sign measurements throughout the trial. Post hoc analysis of
blood pressure and heart rate after 16 weeks of treatment,
when adherence was still relatively high, showed a mean
increase in blood pressure for naltrexone-bupropion com-
pared with placebo averaging only 0.46 mm Hg (95% CI,
0.01-0.92 mm Hg) and mean increase in heart rate of
0.45/min (95% CI, 0.11/min to 0.78/min). These changes
are similar to those observed during previous studies of
naltrexone-bupropion. Adverse effects leading to study drug
discontinuation were relatively common, occurring in 28.1%
of naltrexone-bupropion–treated patients and 8.7% of
placebo-treated patients (P < .001). The most common
adverse effects were gastrointestinal and central nervous sys-
tem symptoms (Table 4).
The events leading to the termination of the study serve
as a valuable reminder of the importance of maintaining con-
fidentiality during ongoing trials. Premature release of
interim data can result in inappropriate prejudgment about
the benefits or risks of the studied therapy andmake comple-
tion of the trial highly problematic. An FDA guidance for
industry explicitly states that interim data from an ongoing
clinical trial should remain confidential and warns that “such
knowledge can bias the outcome of the study by inappropri-
ately influencing its continuing conduct or the plan of
analyses.”19 Prior to public release of the 25% interim data,
the FDA had already appropriately concluded that the knowl-
edge of the results by business interests within the sponsor
constituted an unacceptable breach of confidentiality that
precluded use of the trial tomeet the postapproval regulatory
requirement.11
The findingsof this study illustrate the importanceof con-
fidentiality for early interim data. In this case, the 25% in-
terimdata (Table4) showedapoint estimate for theHR for the
primary endpoint of 0.59, althoughwithwide confidence in-
tervals (95%CI, 0.39-0.90).However, after an additional 25%
of data were collected, the HR increased to 0.88 (99.7% CI,
0.58-1.34). For the final end-of-study analysis, the HR in-
creased further to0.95 (99.7%CI,0.65-1.38), such that anypo-
tential benefit suggested in the earlier analysis was no longer
apparent.
Our study has both strengths and weaknesses. It repre-
sents one of the few cardiovascular outcomes trials of phar-
macological agentsused to treat obesity and,despite early ter-
mination, collected data on a large number of cardiovascular
events. The unplanned early termination represents an im-
portant weakness that prevented the trial from achieving its
full potential. The poor adherence rate was also a weakness
butmay represent the typical pattern observedwith antiobe-
sity pharmacological therapies in clinical practice. The obser-
vationsderivedfromthisstudyprovideuseful insights forother
investigators designing future outcomes trials for other obe-
sity treatments.
Conclusions
Among overweight or obese patients at increased cardiovas-
cular risk, based on the interim analyses performed after 25%
and 50% of planned events, the upper limit of the 95% confi-
dence interval of the HR for MACE for naltrexone-bupropion
treatment, comparedwith placebo, did not exceed 2.0. How-
ever,becauseof theunanticipatedearly terminationof the trial,
it is not possible to assess noninferiority for the prespecified
upper limitof 1.4.Accordingly, thecardiovascular safetyof this
treatment remains uncertain and will require evaluation in a
new adequately powered outcome trial.
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